PharmExec

Novo Nordisk Not Planning Increased Proposal Offer After Metsera Enters $10 Billion Amended Merger Agreement with Pfizer

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims ...

Novo Nordisk Walks Away from $10 Billion Fight--And the Stock Rallies Anyway

Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.
FOX 11 Los Angeles

Dr. Oz jumps in as drug exec collapses during Oval Office press conference

A drug executive collapsed in the Oval Office while President Donald Trump was announcing a deal with drugmakers to reduce ...

Novo Nordisk: Hold On Tightly As The Market Tests Your Faith

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities.

Does Novo Nordisk’s Recent 19.8% Drop Signal a New Opportunity in 2025?

Ever wondered if Novo Nordisk’s stock is a hidden bargain or already priced for perfection? Let’s break down what’s happening beneath the surface so you can invest with clarity. The stock has seen ...
PolitiFact

Novo Nordisk's Gordon Findlay didn't faint Nov. 6, 2025, in the Oval Office. He wasn't even there

Gordon Findlay is a Novo Nordisk manager based in Switzerland who didn’t attend the White House’s Nov. 6 drug pricing announcement. Robert F. Kennedy Jr. wasn’t fleeing the scene, a White House ...
Zacks.com on MSN

Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.